Ge Mengqian, Chen Yuying, Wu Fan, Luo Dingcun
The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People's Hospital, Hangzhou, China.
Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Gland Surg. 2025 Jul 31;14(7):1283-1294. doi: 10.21037/gs-2025-119. Epub 2025 Jul 28.
Large number lymph node metastases (LNLNMs) in papillary thyroid carcinoma (PTC) significantly increase recurrence risk, yet preoperative prediction remains challenging. This study aimed to develop a predictive model integrating blood inflammatory markers and clinical features to identify patients with high-risk LNLNM.
A retrospective cohort of 731 patients with PTC who underwent thyroid surgery at Hangzhou First People's Hospital between September 2021 and October 2022 was included. These patients were divided into a model group (n=513) and a validation group (n=218) at a 7:3 ratio. Analyzed variables included age, gender, absolute values of neutrophils (N), monocytes (M), platelets (Plt), and lymphocytes (L), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammatory index (SII), and tumor diameter and multifocality. Independent risk factors for LNLNM were identified through univariate and multivariate logistic regression analyses, and a risk prediction model was subsequently constructed. Model performance was assessed via receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow (HL) test, calibration curves, and decision curve analysis (DCA).
Age, tumor diameter, Plt, and NLR were identified as independent risk factors for LNLNM in patients with PTC. A predictive model was developed to evaluate the risk of LNLNM, with an area under the curve (AUC) of 0.827 (95% CI: 0.784-0.870; P<0.001) and the specificity and sensitivity were both 75.8%. The AUC of the validation group was 0.824 (95% CI: 0.757-0.890; P<0.001), with a specificity of 79.5% and a sensitivity of 76.9%. Furthermore, the model demonstrated good calibration in the HL test and favorable diagnostic value in calibration curve analysis and DCA.
Age, tumor diameter, Plt count, and NLR count are high-risk factors for LNLNM in patients with PTC, and the predictive model established in combination with the above factors could effectively predict the occurrence of LNLNMs in PTC. This study provides support for surgeons in accurately predicting the possibility of LNLNMs and developing personalized treatment plans before surgery.
甲状腺乳头状癌(PTC)中大量淋巴结转移(LNLNMs)会显著增加复发风险,但术前预测仍具有挑战性。本研究旨在开发一种整合血液炎症标志物和临床特征的预测模型,以识别具有高风险LNLNM的患者。
纳入2021年9月至2022年10月在杭州市第一人民医院接受甲状腺手术的731例PTC患者的回顾性队列。这些患者按7:3的比例分为模型组(n = 513)和验证组(n = 218)。分析的变量包括年龄、性别、中性粒细胞(N)、单核细胞(M)、血小板(Plt)和淋巴细胞(L)的绝对值、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、淋巴细胞与单核细胞比值(LMR)、全身免疫炎症指数(SII)以及肿瘤直径和多灶性。通过单因素和多因素逻辑回归分析确定LNLNM的独立危险因素,随后构建风险预测模型。通过受试者工作特征(ROC)曲线、Hosmer-Lemeshow(HL)检验、校准曲线和决策曲线分析(DCA)评估模型性能。
年龄、肿瘤直径、Plt和NLR被确定为PTC患者LNLNM的独立危险因素。开发了一种预测模型来评估LNLNM的风险,曲线下面积(AUC)为0.827(95%CI:0.784 - 0.870;P < 0.001),特异性和敏感性均为75.8%。验证组的AUC为0.824(95%CI:0.757 - 0.890;P < 0.001),特异性为79.5%,敏感性为76.9%。此外,该模型在HL检验中显示出良好的校准,在校准曲线分析和DCA中具有良好的诊断价值。
年龄、肿瘤直径、Plt计数和NLR计数是PTC患者LNLNM的高危因素,结合上述因素建立的预测模型可有效预测PTC中LNLNMs的发生。本研究为外科医生在术前准确预测LNLNMs的可能性并制定个性化治疗方案提供了支持。